Effects of Bofu-tsusho-san on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed mice

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20022-20044

  Lin, Cheng Hsiu ^a   Kuo, Yueh Hsiung ^b,c   Shih, Chun Ching ^d  

^a FENG YUAN HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

AMP activated protein kinase phosphorylation; Bofu tsusho san; Glucose transporter 4

Indexed keywords

ADIPOCYTOKINE; BOFU TSUSHO SAN; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 4; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BOFU-TSUSHO-SAN; GLUCOSE BLOOD LEVEL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID DIET; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; WEIGHT GAIN; WESTERN BLOTTING; ANALYSIS; ANIMAL; C57BL MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DOWN REGULATION; DRUG EFFECTS; GENETICS; GLUCONEOGENESIS; HYPERLIPIDEMIAS; LIVER; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FATTY ACID SYNTHASES; GLUCONEOGENESIS; GLUCOSE TRANSPORTER TYPE 4; HYPERLIPIDEMIAS; LIVER; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PPAR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIAZOLIDINEDIONES;

EID: 84908519165     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120022     Document Type: Article

References (48)

1. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005, 365, 1333-1346.
2. Kahn, C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994, 43, 1066-1084.
3. Ohno, K.; Chung, H.W.; Maruyama, I.; Tani, T. Bofutsushosan, a traditional Chinese formulation, prevents intimal thickening and vascular smooth muscle cell proliferation induced by balloon endothelial denudation in rats. Biol. Pharm. Bull. 2005, 28, 2162-2165.
4. Yoshida, T.; Sakane, N.; Wakabayashi, Y.; Umekawa, T.; Kondo, M. Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. Int. J. Obes. 1995, 19, 717-722.
5. Morimoto, Y.; Sakata, M.; Ohno, A.; Maegawa, T.; Tajima, S. Effects of Byakko-ka-ninjin-to, Bofu-tsusho-san and Gorei-san on blood glucose level, water intake and urine volume in KKAy mice. Yakugaku Zasshi 2002, 122, 163-168.
6. Daley, P.A.; Krieger, D.R.; Dulloo, A.G.; Young, J.B.; Landsberg, L. Ephedrine, caffeine, and aspirin: Safety and efficacy for the treatment of human obesity. Int. J. Obes. 1993, 17 (Suppl. 1), S73-S78.
7. Suttisri, R.; Lee, I.S.; Kinghorn, D. Plant-derived triterpenoid sweetness inhibitors. J. Ethnopharmacol. 1995, 47, 9-26.
8. Juan, Y.C.; Tsai, W.J.; Lin, Y.L.; Wang, G.J.; Cheng, J.J.; Yang, H.Y.; Hsu, C.Y.; Liu, H.K. The novel anti-hyperglycemic effect of Paeoniae radix via the transcriptional suppression of phosphoenopyruvate carboxykinase (PEPCK). Phytomed 2010, 17, 626-634.
9. Bu, Y.; Shi, T.; Meng, M.; Kong, G.; Tian, Y.; Chen, Q.; Yao, X.; Feng, G.; Chen, H.; Lu, Z. A novel screening model for the molecular drug for diabetes and obesity based on tyrosine phosphatase Shp2. Bioorg. Med. Chem. Lett. 2011, 21, 874-878.
10. Kim, C.-J.; Lim, J.-S.; Cho, S.-K. Anti-diabetic agents from medical plants inhibitory activity of Schizonepetae tenuifolia spikes on the diabetogenesis by streptozotocin in mice. Arch. Pharm. Re. 1996, 19, 441-446.
11. Kim, K.S.; Ezaki, O.; Ikemoto, S.; Itakura, H. Effects of Platycodon grandiflorum feeding on serum and liver lipid concentrations in rats with diet-induced hyperlipidemia. J. Nutr. Sci. Vitaminol. 1995, 41, 485-491.
12. Mueckler, M. Facilitative glucose transporters. Eur. J. Biochem. 1994, 219, 713-725.
13. Bryant, N.J.; Govers, R.; James, D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 2002, 3, 267-277.
14. Watson, R.T.; Pessin, J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog. Horm. Res. 2001, 56, 175-193.
15. Sujatha, S.; Anand, S.; Sangeetha, K.N.; Shilpa, K.; Lakshmi, J.; Balakrishnan, A.; Lakshmi, B.S. Biological evaluation of (3b)-Stigmast-5-en-3-ol as potent anti-diabetic agent in regualting glucose transport using in vitro model. Int. J. Diabetes Mell. 2010, 2, 101-109.
16. Huang, S.; Czech, M.P. The GLUT4 glucose transporter. Cell Metab. 2007, 5, 237-252.
17. Zhou, G.; Myers, R.; Li, Y.; Chen, T.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 2001, 108, 1167-1174.
18. Foretz, M.; Taleux, N.; Guigas, B.; Horman, S.; Beauloye, C.; Andreelli, F.; Bertrand, L.; Viollet, B. Regulation of energy metabolism by AMPK: A novel therapeutic approach for the treatment of metabolic and cardiovascular diseases. Med. Sci. (Paris) 2006, 22, 381-383.
19. Viollet, B.; Lantier, L.; Devin-Leclerc, J.; Hebrard, S.; Amouyal, C.; Mounier, R.; Foretz, M.; Andreelli, F. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci. 2009, 14, 3380-3400.
20. Musi, N. AMP-activated protein kinase and type 2 diabetes. Curr. Med. Chem. 2006, 13, 583-589.
21. Petro, A.E.; Cotter, J.; Cooper, D.A.; Peters, J.C.; Surwit, S.J.; Surwit, R.S. Fat, carbohydrate and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 2004, 53, 454-457.
22. Stein, S.C.; Woods, A.; Jones, N.A.; Davison, M.D.; Carling, D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 2000, 345, 437-443.
23. Tripathy. S.; Torres-Gonalez, M.; Jump, D.B. Elevated hepatic acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J. Lipid Res. 2010, 51, 2642-2654.
24. Gabriely, I.; Barzilai, N. Surgical removal of visceral adipose tissue: Effects on insulin action. Curr. Diabetes Rep. 2003, 3, 201-206.
25. Iglesias, M.A.; Ye, J.M.; Frangioudakis, G.; Saha, A.K.; Tomas, E.; Ruderman, N.B.; Cooney, G.J.; Kraegen, E.W. AICAR administration causes an apparent enhancement of muscle and liver action in insulin-resistant high-fat-fed rats. Diabetes 2002, 51, 2886-2894.
26. Ye, J.M.; Ruderman, N.B.; Kraegen, E.W. AMP-activated protein kinase and malonyl-CoA: Targets for treating insulin resistance? Drug Discov. Today: Therap. Strateg. 2005, 2, 157-163.
27. Guignot, L.; Mithieux, G. Mechanisms by which insulin, associated or not with glucose, may inhibit hepatic glucose production in the rat. Am. J. Physiol. 1999, 227, 984-989.
28. Berg, J.M.; Tymoczko, J.L.; Stryer, L. Glycolysis and glyconeogenesis. In Stryer Biochemistry; Berg J.M., Tymoczko, J.L., Eds.; WH Freeman and Company: New York, NY, USA, 2001; pp. 425-464.
29. Sil, R.; Ray, D.; Chakraborti, A.S. Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. Indian J. Exp. Biol. 2013, 51, 129-138.
30. Chia, Y.Y.; Liong, S.Y.; Ton, S.H.; Kadir, K.A. Amelioration of glucose homeostasis by glycyrrhizic acid through gluconeogenesis rate-limiting enzymes. Eur. J. Pharmacol. 2012, 377, 197-202.
31. Wu, S.Y.; Wang, G.F.; Liu, Z.Q.; Rao, J.J.; Lu, L.; Xu, W.; Wu, S.G.; Zhang, J.J. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol. Sin. 2009, 30, 202-208.
32. Ma, T.; Huang, C.; Zong, G.; Zha, D.; Meng, X.; Li, J.; Tang, W. Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. J. Pharmacol. 2011, 63, 587-593.
33. Fryer, L.G.; Parbu-Patel, A.; Patel, A. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 2002, 277, 25226-25232.
34. Wong, W.T.; Tian, X.Y.; Xu, A.; Yu, J.; Lau, C.W.; Hoo, R.L.C.; Wang, Y.; Lee, V.W.Y.; Lam, K.S.L.; Vanhoutte, P.M.; et al. Adiponectin is required for PPARγ- mediated improvement of endothelial function in diabetic mice. Cell Metab. 2011, 14, 104-115.
35. Zhou, M.; Xu, A.; Lam, K.S.; Tam, P.K.; Che, C.M.; Chan, L.; Lee, I.K.; Wu, D.; Wang Y. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. J. Hepatol. 2010, 53, 1108-1116.
36. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; KITA, S.; Ueki, K.; et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8, 1288-1295.
37. Karbowska, J.; Kochan, Z. Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J. Physiol. Pharmacol. 2006, 57 (Suppl 6), 103-113.
38. Mancini, F.P.; Lanni, A.; Sabatino, L.; Moreno, M.; Giannino, A.; Contaldo, F.; Colantuoni, V.; Goglia, F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001, 491, 154-158.
39. Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Hasty, A.H.; Osuga, J.; Tamura, Y.; Shionoiri, F.; Lizuka, Y.; Ohashi, K.; Harada, K.; et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 1999, 274, 35832-35839.
40. Patel, D.D.; Knight, B.L.; Wiggins, D.; Humphreys, S.M.; Gibbons, G.F. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J. Lipid Res. 2001, 42, 328-337.
41. Staels, B.; Fruchart, J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54, 2460-2470.
42. Chaput, E.; Saladin, R.; Silvestre, M.; Edgar, A.D. Fenofibrate and rosiglitazone lower triglycerides with opposing effects on body weight. Biochem. Biophys. Commun. 2000, 271, 445-450.
43. Shih, C.C.; Lin, C.H.; Lin, W.L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res. Clin. Pract. 2008, 81, 134-143.
44. Folch, J.; Lees, M.; Sloan-Stanley, G.H. A sample method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226, 497-509.
45. Shen, Q.W.; Jones, C.S.; Kalchayanand, N.; Zhu, M.J.; Du, M.J. Effect of dietary alpha-lipoic acid on growth, body composition, muscle pH, and AMP-activated protein kinase phosphorylation in mice. Anim. Sci. 2005, 83, 2611-2617.
46. Shih, C.C.; Ciou, J.L.; Lin, C.H.; Wu, J.B.; Ho, H.Y. Cell suspension culture of Eriobotrya japonica regulates the diabetic and hyperlipidemic signs of high-fat-fed mice. Molecules 2013, 18, 2726-2753.
47. Klip, A.; Ramlal, T.; Young, D.A.; Holloszy, J.O. Insulin-induced translocation of glucose transporters in rat hindlimb muscles. FEBS Lett. 1987, 224, 224-230.
48. Shih, C.C.; Lin, C.H.; Lin, W.L.; Wu, J.B. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J. Ethnopharmacol. 2009, 123, 82-90.